Repligen (RGEN) AI Stock Analysis

• Market Cap: $7.12B
• Dividend Yield: N/A
• Average Volume (3M): 901.73K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.39
• Revenue Growth: 8.73%
• EPS Growth: -245.82%
• Country: US
• Employees: 1,778
• Sector: Healthcare
• Sector Strength: 49
• Industry: Medical - Instruments & Supplies
• EPS (TTM): 0.37
• Shares Outstanding: 56,257,618
• 10 Day Avg. Volume: 808,311
• 30 Day Avg. Volume: 901,729
• PEG Ratio: 1.84
• Price to Book (P/B): 4.08
• Price to Sales (P/S): 12.69
• P/FCF Ratio: 56.51
• Enterprise Value/Market Cap: 0.98
• Enterprise Value/Revenue: 10.85
• Enterprise Value/Gross Profit: 25.40
• Enterprise Value/Ebitda: 58.91
• 1Y Price Target: $177.17
• Price Target Upside: 42.49% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 13

• Rating: 58 Neutral
• Price Target: $126.00 ▲(1.34% Upside)

Repligen's overall stock score is driven by its mixed financial performance and technical indicators suggesting bearish momentum. The positive outlook from the earnings call, with strong organic growth and increased guidance, partially offsets the valuation concerns due to negative earnings. The company's strategic focus on non-COVID growth areas and operational efficiency are key strengths.

Positive Factors

Earnings

Repligen's revenue of $182.4 million exceeded both the estimate of $177.1 million and the consensus of $175.2 million, highlighting strong financial performance.

Growth Strategy

Repligen expects to double its revenues in the medium-term with minimal contribution from mergers and acquisitions, indicating a robust organic growth strategy.

Market Position

Repligen's differentiated product portfolio is yielding outsized growth in a normalizing bioprocessing market, with non-COVID organic growth up 17% and orders up over 20% year-over-year.

Negative Factors

Earnings Guidance

Repligen expects full-year 2025 GAAP net earnings of $0.76 - $0.85 per diluted share, down from the original guidance range of $0.90 - $0.99 per diluted share.

Margin Pressure

Margins missed due to product mix dynamics, creating a 300-basis-point gross margin headwind.

Market Sentiment

A recent downturn in gene therapy sentiment due to recent news creates a 1% headwind in the newly raised FY25 guidance.

Repligen Business Overview & Revenue Model

Company Description

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products. The company's chromatography products include OPUS pre-packed chromatography columns, which are used in the purification of biologics; and OPUS smaller-scale columns that are used in the high throughput process development screening, viral clearance validation studies, and scale down validation of chromatography processes. It also offers ELISA test kits; and chromatography resins under the CaptivA brand. In addition, the company provides filtration products, such as XCell Alternating Tangential Flow systems that are filtration devices used in upstream perfusion and cell culture processing; TangenX flat sheet cassettes, which are used in downstream biologic drug concentration and formulation processes; KrosFlo tangential flow filtration and tangential flow depth filtration systems; Spectra/Por laboratory and process dialysis products, and SpectraFlo dynamic dialysis systems; and ProConnex single-use hollow fiber. Further, it provides process analytics products, such as slope spectroscopy systems under the SoloVPE, FlowVPE, and FlowVPX brands. The company sells its products to life sciences, biopharmaceutical, and diagnostics companies; laboratory researchers; and contract manufacturing organizations. Repligen Corporation has collaboration agreements with Navigo Proteins GmbH to develop multiple affinity ligands. Repligen Corporation was incorporated in 1981 and is headquartered in Waltham, Massachusetts.

How the Company Makes Money

Repligen generates revenue primarily through the sale of its bioprocessing products and technologies. Key revenue streams include the sale of chromatography resins, filtration products, and other consumables used in biomanufacturing processes. The company also derives income from its services related to product development and customer support. Significant partnerships with leading biopharmaceutical companies enhance its market presence and contribute to its earnings by ensuring consistent demand for its products. Additionally, Repligen's focus on innovation and expansion into new markets helps to drive growth and diversify its revenue base.

Repligen Financial Statement Overview

Summary

Repligen's financial performance is mixed. The company shows strengths in its balance sheet with low leverage and a strong equity position. However, challenges in profitability, with declining net income and EBIT margins, are notable concerns. Operational cash flow remains positive despite these issues.

Income Statement

Repligen's revenue shows a marginal growth from the previous year, but has declined from 2022. The gross profit margin for TTM is approximately 54.88%, indicating decent cost management. However, the company is experiencing negative net income and EBIT margins, highlighting profitability challenges. The EBITDA margin is positive at 13.80%, suggesting some operational efficiency.

Balance Sheet

The company's balance sheet is relatively strong with a debt-to-equity ratio of approximately 0.34, indicating low leverage. The equity ratio is around 69.60%, reflecting a healthy balance of equity financing. However, the return on equity is negative due to net losses, which is a concern for investors seeking returns.

Cash Flow

Repligen's cash flow statement shows a decrease in free cash flow compared to the annual report, with a negative free cash flow growth rate. The operating cash flow to net income ratio is negative due to the net loss, but operating cash flow remains positive, which indicates underlying operational strength despite profitability concerns.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	645.66M	634.44M	632.36M	801.54M	670.53M	366.26M
Gross Profit	275.86M	274.64M	308.83M	455.71M	391.25M	209.63M
EBITDA	118.93M	82.10M	127.77M	246.93M	211.56M	101.62M
Net Income	-25.37M	-25.51M	35.60M	185.96M	128.29M	59.93M
Balance Sheet
Total Assets	2.85B	2.83B	2.83B	2.52B	2.36B	1.90B
Cash, Cash Equivalents and Short-Term Investments	697.23M	757.36M	751.32M	623.76M	603.81M	717.29M
Total Debt	683.70M	686.25M	711.80M	422.96M	366.05M	275.42M
Total Liabilities	866.66M	856.95M	866.34M	613.96M	608.29M	373.74M
Stockholders Equity	1.99B	1.97B	1.97B	397.27M	1.75B	65.77M
Cash Flow
Free Cash Flow	117.60M	142.49M	74.93M	38.74M	47.74M	36.28M
Operating Cash Flow	145.69M	175.39M	113.92M	172.08M	119.02M	62.63M
Investing Cash Flow	-152.13M	-86.38M	-123.28M	-233.24M	-221.17M	-201.38M
Financing Cash Flow	-78.96M	-82.90M	248.96M	-13.34M	961.00K	305.92M

Repligen Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 124.34
• 50DMA: Positive
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For RGEN, the sentiment is Positive. The current price of 124.34 is above the 20-day moving average (MA) of 118.71, above the 50-day MA of 122.70, and below the 200-day MA of 138.21, indicating a neutral trend. The MACD of -0.08 indicates Negative momentum. The RSI at 54.95 is Neutral, neither overbought nor oversold. The STOCH value of 90.26 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for RGEN.

Repligen Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
TFX	73 Outperform	$5.37B	28.60	4.36%	1.13%	1.11%	-23.73%
MMSI	72 Outperform	$5.05B	43.30	8.60%	―	10.14%	0.04%
STVN	61 Neutral	$6.05B	41.41	9.55%	0.28%	5.95%	7.73%
RGEN	58 Neutral	$7.12B	―	-0.68%	―	8.73%	-245.82%
MASI	51 Neutral	$8.25B	116.65	-20.54%	―	-8.36%	-669.36%
Sector *	47 Neutral	C$213.29M	-1.44	-30.58%	3.10%	19.48%	-0.04%
ICUI	45 Neutral	$2.76B	―	-1.78%	―	2.95%	47.92%

Repligen Corporate Events

Repligen Holds Annual Shareholders Meeting, Key Decisions Made

On May 15, 2025, Repligen Corporation held its Annual Meeting of Shareholders, where several key decisions were made. The shareholders elected ten directors to the board, ratified the appointment of Ernst & Young LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2025, approved the compensation of the company’s executive officers, and sanctioned an amendment to the Certificate of Incorporation to limit the liability of certain officers. These decisions are expected to influence Repligen’s governance and operational strategies moving forward.

The most recent analyst rating on (RGEN) stock is a Buy with a $225.00 price target. To see the full list of analyst forecasts on Repligen stock, see the RGEN Stock Forecast page.